

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs	
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS				
SWOG	S1320-Adv, BRAF mut, Inter v Contin	1	Y 1	Lead-in Continuous Dosing	280	229	45	14	9	5	1	09/19/2014	221	98
						229	45	14	9	5	1			
		2	Y 2	Continuous Dosing	237	95	21	6	1	0	0	09/19/2014		
				3 Intermittent Dosing		90	19	4	0	0	0			
						185	40	10	1	0	0			
	S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro)	1	Y 1	MK-3475 (pembrolizumab)	77	17	14	7	4	1	0	02/06/2017	90	42
						17	14	7	4	1	0			
	S1607-MELAN, Adv, T-VEC, MK-3475	1	Y 1	T-VEC + MK-3475(pembrolizumab)	64	7	7	7	5	3	0	06/05/2018	29	17
						7	7	7	5	3	0			
	S1616-MELAN, Adv, Ipilimumab ± Nivolumab	1	Y 1	Ipilimumab	94	8	8	5	0	0	0	10/23/2017	234	95
				2 Nivolumab + Ipilimumab		18	16	11	4	2	0			
						26	24	16	4	2	0			
Yes	EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	1	E	Total Registrations		30	7	4	3	0	0	11/03/2015	349	141
						30	7	4	3	0	0			
		2	E	Total Registrations		12	7	5	2	0	0	11/03/2015		
						12	7	5	2	0	0			
	EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim	1	E	Total Registrations		36	0	0	0	0	0	03/25/2016	218	95
						36	0	0	0	0	0			